Stress-opioid interactions: A comparison of morphine and methadone

Pharmacological Reports

Volumn 61, Issue 3, 2009, Pages 424-435

  Taracha, Ewa ^a   Mierzejewski, Paweł ^a   Lehner, Małgorzata ^a   Chrapusta, Stanisław J ^b   Kała, Maria ^c   Lechowicz, Wojciech ^c   Hamed, Adam ^d   Skórzewska, Anna ^a   Kostowski, Wojciech ^a   Płaźnik, Adam ^a,d  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c INSTITUTE OF FORENSIC RESEARCH   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Catalepsy; Cortex; Fos protein; Nucleus accumbens; Opioid; Pain; Stress; Striatum

Indexed keywords

METHADONE; MORPHINE SULFATE; PROTEIN FOS;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CATALEPSY; CELL ACTIVITY; CELL COUNT; CINGULATE GYRUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG POTENCY; EXPERIMENTAL STUDY; HOT PLATE TEST; IMMUNOHISTOCHEMISTRY; LATENT PERIOD; LOW DRUG DOSE; MALE; MENTAL STRESS; NERVE CELL; NONHUMAN; NUCLEUS ACCUMBENS; PHARMACOLOGICAL STIMULATION; PROTEIN EXPRESSION; PUTAMEN; RAT; SINGLE DRUG DOSE; SOMATOSENSORY CORTEX;

ANALGESICS, OPIOID; ANIMALS; BODY TEMPERATURE; BRAIN; CATALEPSY; DRUG INTERACTIONS; MALE; METHADONE; MORPHINE; PAIN MEASUREMENT; PROTO-ONCOGENE PROTEINS C-FOS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; STRESS, PHYSIOLOGICAL;

EID: 67651146496     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70083-0     Document Type: Article

References (45)

1. Aderjan RE, Skopp C: Formation and clearance of active and inactive metabolites of opiates in humans. Ther Drug Monit, 1998, 20, 561-569.
2. Ahtee L: Catalepsy and stereotypies in rats treated with methadone: relation to striatal dopamine. Eur J Pharmacol, 1974, 27, 221-230.
3. Athanasos P, Smith CS, White JM, Somogyi AA, Bochner F, Ling W: Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. Pain, 2006, 120, 267-275.
4. Badiani A, Oates MM, Robinson TE: Modulation of morphine sensitization in the rat by contextual stimuli. Psychopharmacology, 2000, 151, 273-282.
5. Bardo MT, Gehrke BJ, Shortridge BE, Rauhut AS: Effects of β-funaltrexamine and naloxonazine on single-trial morphine-conditioned place preference and locomotor activity. Pharmacol Biochem Behav, 2003, 74, 617-622.
6. Bhalla S, Matwyshyn G, Gulati A: Potentiation of morphine analgesia by BQ123, an endothelin antagonist. Peptides, 2002, 23, 1837-1845.
7. Bland ST, Twining C, Schmid MJ, Der-Avakian A, Watkins LR, Maier SF: Stress potentiation of morphine-induced dopamine efflux in the nucleus accumbens shell is dependent upon stressor uncontrollability and is mediated by the dorsal raphe nucleus. Neuroscience, 2004, 126, 705-715.
8. Bontempi B, Sharp FR: Systemic morphine-induced Fos protein in the rat striatum and nucleus accumbens is regulated by opioid receptors in the substantia nigra and ventral tegmental area. J Neurosci, 1997, 17, 8596-8612.
9. Bulka A, Plesan A, Xu XJ, Wiesenfeld-Hallin Z: Reduced tolerance to the anti-hyperalgesic effect of methadone in comparison to morphine in rat model of mononeuropathy. Pain, 2002, 95, 103-109.
10. Chang SL, Squinto SP, Harlan RE: Morphine activation of c-Fos expression in rat brain. Biochem Biophys Res Commun, 1988, 157, 698-704.
11. Dimsdale JE, Norman D, DeJardin D, Wallach MS: The effects of opioid on sleep architecture. J Clin Sleep Med, 2007, 3, 33-36.
12. Doverty M, Somogyi AA, White JM, Bochner F, Beare CH, Menelaou A, Ling W: Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain, 2001, 93, 155-163.
13. Eap CB, Buclin T, Baumann P: Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet, 2002, 41, 1153-1193.
14. Ferguson SM, Thomas MJ, Robinson TE: Morphine-induced c-fos mRNA expression in striatofugal circuits: modulation by dose, environmental context, and drug history. Neuropsychopharmacology, 2004, 29, 1664-1674.
15. Filipkowski RK: Inducing gene expression in barrel cortex - focus on immediate early genes. Acta Neurobiol Exp, 2000, 60, 411-418.
16. Frankel PS, Harlan RE, Garcia MM: Chronic administration of morphine alters immediate-early gene expression in the rat forebrain of post-dependent rats. Brain Res, 1999, 835, 204-212.
17. Garcia MM, Brown H, Harlan RE: Alternations in immediate-early gene proteins in the rat forebrain induced by acute morphine injection. Brain Res, 1995, 692, 23-40.
18. Gourlay GK: Advances in opioid pharmacology. Support Care Cancer, 2005, 13, 153-159.
19. He L, Whistler JL: An opiate cocktail that reduces morphine tolerance and dependence. Curr Biol, 2005, 15, 1028-1033.
20. Kreek MJ: Drug addictions. Molecular and cellular end-points. Ann NY Acad Sci, 2001, 937, 27-49.
21. Kreek MJ, Nielsen DA, Butelman ER, LaForge KS: Genetic influences of impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci, 2005, 8, 1450-1457.
22. Le Moal M, Koob GF: Drug addiction: pathways to the disease and pathophysiological perspectives. Eur Neuropsychopharmacol, 2007, 17, 377-393.
23. Lehner M, Taracha E, Skorzewska A, Maciejak P, Wislowska-Stanek A, Zienowicz M et al.: Behavioral, immunocytochemical and biochemical studies in rats differing in their sensitivity to pain. Behav Brain Res, 2006, 171, 189-198.
24. Ling GS, Umans JG, Inturrisi CE: Methadone: radioimmunoassay and pharmacokinetics in the rat. J Pharmacol Exp Ther, 1981, 217, 147-151.
25. Martin TS, Kahn W, Cholders SR: Differential regional effects of methadone maintenance compared to heroin dependence on μ-opioid receptor desensitization in rat brain. Synapse, 2007, 61, 176-184.
26. Mayer P, Erdtmann-Vourliotis M, Riechert U, Ammon S, Höllt V: Mild stress sensitizes the brain's response to morphine. Mol Brain Res, 2002, 104, 143-147.
27. Mierzejewski P, Koros E, Goldberg SR, Kostowski W, Stefański R: Intravenous self-administration of morphine and cocaine: a comparative study. Pol J Pharmacol, 2003, 55, 713-726.
28. Morley JS, Makin MK: The use of methadone in cancer pain poorly responsive to other opioids. Pain Rev, 1998, 5, 51-58.
29. 8]methadone. J Pharm Sci, 1982, 71, 40-43.
30. Paolone G, Conversi D, Caprioli D, Del Bianco P, Nencini P, Cabib S, Badiani A: Modulatory effect of environmental context and drug history on heroin-induced psychomotor activity and Fos protein in the rat brain. Neuropsychopharmacology, 2007, 32, 2611-2623.
31. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates, 4th edn., Academic Press, San Diego, 1998.
32. Rauhala P, Idänpään-Heikkilä JJ, Tuominen RK, Männistö PT: Differential dissapearance of tolerance to thermal, hormonal and locomotor effects of morphine in the male rat. Eur J Pharmacol, 1995, 285, 69-77.
33. Sagar SM, Sharp FR, Curran T: Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science, 1988, 240, 1328-1331.
34. Singh ME, Verty AN, Price I, McGregor IS, Mallet PE: Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716. Neuropharmacology, 2004, 47, 1157-1169.
35. Snow AE, Dewey WL: A comparison of antinociception induced by foot shock and morphine. J Pharmacol Exp Ther, 1983, 227, 42-50.
36. Taracha E, Chrapusta SJ, Lehner M, Skórzewska A, Maciejak P, Szyndler J, Płaźnik A: Morphine and methadone pre-exposures differently modify brain regional Fos protein expression and locomotor activity responses to morphine challenge in the rat. Drug Alcohol Depend, 2008, 97, 21-32.
37. Taracha E, Lehner M, Wisłowska-Stanek A, Zienowicz M, Maciejak P, Bidziński A, Skórzewska A et al.: Effects of methadone and morphine on c-Fos expression in the rat brain: similarities and differences. Pharmacol Rep, 2006, 58, 120-124.
38. Terpening CM, Johnson WM: Methadone as an analgesic: a review of risks and benefits. WV Med J, 2007, 103, 14-18.
39. Thomas PT, House RV, Bhargava HN: Direct cellular immunomodulation produced by diacetylmorphine (heroin) or methadone. Gen Pharmacol, 1995, 26, 123-130.
40. Tzschentke TM, Schmidt W: Morphine-induced catalepsy is augmented by NMDA receptor antagonists, but is partially attenuated by an AMPA receptor antagonist. Eur J Pharmacol, 1996, 295, 137-146.
41. Vanderschuren LJ, De Vries TJ, Wardeh G, Hogenboom FA, Schoffelmeer AN: A single exposure to morphine induces long-lasting behavioural and neurochemical sensitization in rats. Eur J Neurosci, 2001, 14, 1533-1538.
42. Xiong W, Yu LC: Involvement of mu- and kappa-opioid receptors in morphine-induced antinociception in the nucleus accumbens of rats. Neurosci Lett, 2006, 399, 167-170.
43. Zhu H, Lee MS, Agatsuma S, Hiroi N: Pleiotropic impact of constitutive fosB inactivation on nicotine-induced behavioral alterations and stress-related traits in mice. Hum Mol Gen, 2007, 16, 820-836.
44. Zienowicz M, Wisłowska-Stanek A, Lehner M, Taracha E, Maciejak P, Sobolewska A, Szyndler J et al.: Fluoxetine-induced anxiety and nervousness. Pharmacol Rep, 2006, 58, 115-119.
45. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, Meyer CR et al.: Regional mu receptor regulation of sensory and affective dimensions of pain. Science, 2001, 293, 311-315.